1
|
Mozdon MA, Ponomarev RV, Tsvetaeva NV, Shabrin AV, Ermachenkova EI, Larichev SE, Lukina EA. [Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report]. TERAPEVT ARKH 2023; 95:580-585. [PMID: 38159009 DOI: 10.26442/00403660.2023.07.202303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 09/29/2023] [Indexed: 01/03/2024]
Abstract
Rendu-Osler-Weber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.
Collapse
Affiliation(s)
- M A Mozdon
- National Medical Research Center for Hematology
| | | | | | - A V Shabrin
- City Clinical Hospital №17
- Pirogov Russian National Research Medical University
| | | | - S E Larichev
- City Clinical Hospital №17
- Pirogov Russian National Research Medical University
| | - E A Lukina
- National Medical Research Center for Hematology
| |
Collapse
|
2
|
Sysoeva EP, Ponomarev RV, Lukina KA, Chavynchak RB, Korotkova SB, Zhilyaeva MV, Nikitina EG, Markova OA, Gapchenko EV, Shuster AM, Kudlay DA, Lukina EA. Evaluation of the efficacy and safety of the biosimilar drug Glurazyme (imiglucerase) in patients with Gaucher disease type 1. Gematologiâ i transfuziologiâ 2020. [DOI: 10.35754/0234-5730-2020-65-1-8-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Background. Gaucher disease (GD) is a rare hereditary condition, which represents the most common form of lysosomal storage diseases. Enzyme replacement therapy (ERT) with recombinant glucocerebrosidase is used for the treatment of type 1 and type 3 GD. Imiglucerase (recombinant glucocerebrosidase) is the first biotechnological ERT medication possessing confirmed clinical efficacy and safety.Aim. To compare the efficacy and safety of the biosimilar drug Glurazyme and the reference drug Cerezyme during ERT therapy in patients with type 1 GD.Materials and methods. Thirty patients aged from 19 to 63 years (33 ± 9.7 years) with a stable course of type 1 GD were enrolled in the study. The patients were randomly divided into two equal treatment groups, one of which received Glurazyme and the other received the reference drug Cerezyme. In both groups, the drugs were used in doses of 15–40 U/kg intravenously once every 14 days for 52 weeks.Results. At the end of the study, at week 52 (primary endpoint of efficacy), both groups demonstrated a similar increase in hemoglobin concentration compared to the baseline data. In both groups, the average increase in hemoglobin concentration was 4.8 g/l, with this parameter varying between the groups by 0.1 g/l. At week 52, the calculated 95% confidence interval for the difference in hemoglobin concentration did not cross the non-inferiority margin of 18 g/l, which had been specified as the lower level of drug efficacy. This led to the conclusion that the studied drug Glurazyme is not inferior to Cerezyme in terms of efficacy. A comparison of the treatment groups by secondary endpoints of efficacy revealed: no decrease in hemoglobin concentration by more than 20 % in both groups; no differences between the groups by the number of patients with a change in platelet concentration relative to the baseline values; no increase in the spleen and liver volume by more than 20 and 10 %, respectively, in both groups. The doses of the drug under study and the reference drug remained unchanged during the research. The concentration of chemokine CCL-18 decreased slightly in 10 patients (64.3 %) and 6 patients (40 %) in the Glurazyme group and the Cerezyme group, respectively. The proportion of patients with improved physical and mental health components was 57.1 and 57.1 %, respectively, in the Glurazyme group compared to 73.3 and 60 %, respectively, in the Cerezyme group. Changes in the state of the bone tissue and the reserves of accumulated metabolites in the bone marrow showed a similar decrease in the severity of bone marrow infiltration in both groups.Conclusions. Glurazyme and Cerezyme showed comparable parameters of efficacy and safety in patients with GD type 1 during long-term enzyme replacement therapy.
Collapse
|
3
|
Ponomarev RV, Lukina KA, Sysoeva EP, Chavynchak RB, Solovyeva AA, Yatsyk GA, Kulikov SM, Lukina EA. REDUCED DOSING REGIMEN OF ENZYME REPLACEMENT THERAPY IN ADULT PATIENTS WITH TYPE I GAUCHER DISEASE: PRELIMINARY RESULTS. Gematologiâ i transfuziologiâ 2019. [DOI: 10.35754/0234-5730-2019-64-3-331-341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Introduction. Gaucher disease (GD) belongs to the group of lysosomal storage diseases. Enzyme replacement therapy (ERT) is considered to be the current standard in GD treatment. No reduced ERT regimen has thus far been developed. Aim. To develop an optimal reduced ERT regimen for adult patients with type I GD, which is scientifically and economically viable.Materials and methods. The study included 100 adult patients with type I GD who achieved treatment goals following at least two years of the standard ERT regimen. Patients were prescribed a reduced ERT regimen, which consisted in increasing the interval between the infusions of the recombinant enzyme up to 4 weeks, at a dose of 15–20 units/kg of body weight. The efficacy of the reduced ERT regimen was assessed once every 12 months according to main GD parameters. The follow-up period in the study ranged from 12 to 36 months.Results. The patients with type I GD who achieved treatment goals following the standard ERT regimen and were then prescribed a reduced ERT regimen retained a stable therapeutic effect of the initial treatment according to all parameters: no clinically significant differences found in haemoglobin and platelet levels, spleen size and specific infiltration of femur bone marrow.Conclusion. An increase in the intervals between infusions of the recombinant glucocerebrosidase up to 4 weeks for 12, 24 and 36 months did not lead to worsening of the laboratory and instrumental parameters associated with GD.
Collapse
|
4
|
Ponomarev RV, Lukina EA. [Enzyme replacement therapy in adult patients with type I Gaucher disease]. TERAPEVT ARKH 2019; 91:127-131. [PMID: 32598746 DOI: 10.26442/00403660.2019.07.000327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Indexed: 11/22/2022]
Abstract
Enzyme replacement therapy (ERT) is the standard for the treatment of Gaucher disease (GD). A lifelong intravenous administration of a recombinant analogue of human glucocerebrosidase compensates for the functional deficiency of its own enzyme. The use of ERT has changed the clinical phenotype of GD, a severe progressive disease has been turned into the status of an asymptomatic metabolic defect. At the same time, a reduced dosing ERT regimen applied in Gaucher patients who had achieved therapeutic goals has not yet been developed.
Collapse
|
5
|
Soloveva AA, Ponomarev RV, Lukina KA, Mamonov VE, Khomenko VA, Kostina IE, Yatsyk GA, Lukina EA. Differential radiological diagnosis of tuberculous sacroiliitis and bone involvement in Gaucher disease: a clinical case. TERAPEVT ARKH 2019; 91:84-88. [PMID: 31090377 DOI: 10.26442/00403660.2019.01.000035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Differential diagnosis of bone involvement in patients with Gaucher disease can be challenging. Other diseases with similar radiological signs should be ruled out. Here we present a clinical case of tuberculous sacroiliitis in the patient with type I Gaucher disease. Advanced radiological methods of examination are described. Our case report proves the necessity of an individual approach to the management of such cohort of patients. Keywords: Gaucher disease, tuberculosis of bones and joints, differential diagnosis, comprehensive treatment.
Collapse
Affiliation(s)
- A A Soloveva
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - R V Ponomarev
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - K A Lukina
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - V E Mamonov
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - V A Khomenko
- Federal Research Central for Tuberculosis, Moscow, Russia
| | - I E Kostina
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - G A Yatsyk
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - E A Lukina
- National Research Center for Hematology of the Ministry of Health of the Russian Federation, Moscow, Russia
| |
Collapse
|
6
|
Ponomarev RV, Model SV, Zozulya NI, Ivanov VA, Podchasov DA, Mershina EA, Sinitsyn VE, Lukina EA. Constrictive pericarditis in a patient with inherited factor VII deficiency. TERAPEVT ARKH 2018; 90:86-90. [PMID: 30701928 DOI: 10.26442/terarkh201890786-90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Constrictive pericarditis (CP) is the final stage of a chronic inflammatory process characterized by fibrous thickening and calcification of the pericardium that impairs diastolic filling, reduces cardiac output, and ultimately leads to heart failure. We present a clinical case of CP in a patient with rare inherited bleeding disorder - factor VII deficiency. Heart failure due to CP was suspected based on clinical symptoms, results of ultrasonic and radiological investigations. The diagnosis was verified by the results of cardiac magnetic resonance imaging. Pericardectomy was performed resulting in significant improvement in the patient's condition.
Collapse
Affiliation(s)
- R V Ponomarev
- National Research Center for Hematology, Moscow, Russia
| | - S V Model
- National Research Center for Hematology, Moscow, Russia
| | - N I Zozulya
- National Research Center for Hematology, Moscow, Russia
| | - V A Ivanov
- Russian Scientific Center for Surgery named B.V. Petrovsky, Moscow, Russia
| | - D A Podchasov
- Russian Scientific Center for Surgery named B.V. Petrovsky, Moscow, Russia
| | - E A Mershina
- Federal Center of Treatment and Rehabilitation, Ministry of Health of the RF, Moscow, Russia
| | - V E Sinitsyn
- Federal Center of Treatment and Rehabilitation, Ministry of Health of the RF, Moscow, Russia
| | - E A Lukina
- National Research Center for Hematology, Moscow, Russia
| |
Collapse
|
7
|
Ponomarev RV, Model SV, Averbukh OM, Gavrilov AM, Galstyan GM, Lukina EA. [Progressive pulmonary hypertension in a patient with type 1 Gaucher disease]. TERAPEVT ARKH 2017; 89:71-74. [PMID: 29171474 DOI: 10.17116/terarkh2017891071-74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Gaucher disease is the most common form of hereditary enzymopathies combined into a group of lysosomal storage diseases. The basis for the disease is a hereditary deficiency of the activity of acid β-glucosidase, a lysosomal enzyme involved in the catabolism of lipids, which results in the accumulation of nonutilized cellular metabolism products in the macrophage lysosomes. The main clinical manifestations of type 1 Gaucher disease are cytopenia, hepatomegaly, and splenomegaly, and bone lesion. One of the atypical clinical manifestations of Gaucher disease is damage to the lungs with the development of pulmonary hypertension, which is usually considered within the underlying disease - the development of pneumosclerosis due to macrophage dysfunction. The paper describes a case of progressive pulmonary hypertension in a patient with type 1 Gaucher disease.
Collapse
Affiliation(s)
- R V Ponomarev
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - S V Model
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - O M Averbukh
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A M Gavrilov
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - G M Galstyan
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - E A Lukina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|